A Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
A Phase 2b, Randomized, Double Blind, Vehicle Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Cream Applied Once or Twice Daily for 6 Weeks in Participants With Mild or Moderate Atopic Dermatitis
Category & Conditions: Skin Diseases and Conditions
Medicine: brepocitinib (PF-06700841)
ClinicalTrials.gov Identifier (NCT): NCT03903822
Protocol ID: B7931022
PrintDownloadOpen Plain Language Summary Result: Click here